NUWE Key Statistics, Chart & Performance
The current stock price of NUWE is 2 USD. In the past month the price decreased by -29.58%. In the past year, price decreased by -95.33%.
NUWE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About NUWE
Company Profile
Nuwellis, Inc. operates as a medical device company. The company is headquartered in Eden Prairie, Minnesota and currently employs 38 full-time employees. The company went IPO on 2012-02-16. The firm is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Company Info
NUWELLIS INC
12988 Valley View Rd
Eden Prairie MINNESOTA 55344 US
CEO: Nestor Jaramillo
Employees: 38
Phone: 19523454200
NUWELLIS INC / NUWE FAQ
Can you describe the business of NUWELLIS INC?
Nuwellis, Inc. operates as a medical device company. The company is headquartered in Eden Prairie, Minnesota and currently employs 38 full-time employees. The company went IPO on 2012-02-16. The firm is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Can you provide the latest stock price for NUWELLIS INC?
The current stock price of NUWE is 2 USD. The price increased by 1.52% in the last trading session.
Does NUWE stock pay dividends?
NUWE does not pay a dividend.
What is the ChartMill rating of NUWELLIS INC stock?
NUWE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for NUWE stock?
NUWELLIS INC (NUWE) currently has 38 employees.
What is the outstanding short interest for NUWELLIS INC?
The outstanding short interest for NUWELLIS INC (NUWE) is 0.52% of its float.
NUWE Technical Analysis
NUWE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NUWE. NUWE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NUWE Financial Highlights
Over the last trailing twelve months NUWE reported a non-GAAP Earnings per Share(EPS) of -1630.02. The EPS increased by 91.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -207.46% | ||
| ROE | -423.19% | ||
| Debt/Equity | 0 |
NUWE Forecast & Estimates
For the next year, analysts expect an EPS growth of 98.39% and a revenue growth -8.15% for NUWE